Withings announced today that it will acquire Impeto Medical and its technology for detecting and tracking peripheral neuropathies.
The financial terms of the deal were not disclosed.
Withings plans to first use the Impeto Medical tech in its Body Scan smart scale platform, which it announced last week at CES 2022. Body Scan boasts a 6-lead electrocardiogram (ECG) and segmental body composition analysis; Withings plans to launch it in the second half of 2022, following CE mark and FDA approval.
Established in 2005, Impeto Medical’s FDA -cleared Sudoscan technology uses an electrical stimulus on the palms of the hands or soles of the feet to check how the sweat glands respond with the release of chloride ions. When small nerve fibers degrade, it reduces sweat gland innervation and impairs sudomotor function.
Diseases including diabetes, Parkinson’s, chemotherapy-induced polyneuropathy, family amyloid polyneuropathy, and Fabry disease can result in small fiber neuropathies. The Sudoscan tech has been licensed and embedded into tens of thousands of devices for companies and hospitals worldwide, according to Withings.
“The company and its team have been important partners to us in the past. Now, as part of Withings, we have an exciting opportunity to continue to deploy together their expertise and Sudoscan technology in the development of a variety of devices that have the potential for people to monitor and manage various disease states from the comfort of their home” Withings CEO Mathieu Letombe said in a news release.
